✨
AI Summary
- KSQ Therapeutics discusses Tumor-Infiltrating Lymphocytes (TILs) for solid tumors.
- Their Phase 1/2 study uses CRISPR to inactivate SOCS1 in TILs.
- Potential applications extend to autoimmune diseases beyond solid tumors.
Guests on This Episode
MB
Micah Benson
1 podcast appearance